Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.19−1.16 (-10.22%)
Close on Nov 12, 2026Market cap $655.77MP/E –Yield –
Cullinan Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Cullinan Therapeutics's enterprise value was $395.82M on Nov 11, 2026, against $339.10M a year earlier. Over the last 5 years it ranged from -$116.22M to $1.09B, with a median of $203.65M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $395.82M | +42.0% |
| 2025 | Dec 31, 2025 | $278.84M | +114.4% |
| 2024 | Dec 31, 2024 | $130.06M | – |
| 2023 | Dec 29, 2023 | -$30.70M | – |
| 2022 | Dec 30, 2022 | -$93.36M | -126.3% |
| 2021 | Dec 31, 2021 | $354.73M | – |
See a number that looks wrong?